We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Walgreens (WBA) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Walgreens Boots Alliance (WBA - Free Report) will announce quarterly earnings of $0.82 per share in its forthcoming report, representing a decline of 29.3% year over year. Revenues are projected to reach $36.48 billion, increasing 4.7% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Walgreens metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- U.S. Retail Pharmacy' will reach $28.55 billion. The estimate indicates a change of +3.5% from the prior-year quarter.
The average prediction of analysts places 'Revenues- International' at $5.83 billion. The estimate indicates a year-over-year change of +3.2%.
It is projected by analysts that the 'Revenues- U.S. Healthcare' will reach $2.06 billion. The estimate suggests a change of +25.8% year over year.
Walgreens shares have witnessed a change of -5.3% in the past month, in contrast to the Zacks S&P 500 composite's +3.1% move. With a Zacks Rank #4 (Sell), WBA is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Walgreens (WBA) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Analysts on Wall Street project that Walgreens Boots Alliance (WBA - Free Report) will announce quarterly earnings of $0.82 per share in its forthcoming report, representing a decline of 29.3% year over year. Revenues are projected to reach $36.48 billion, increasing 4.7% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Walgreens metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- U.S. Retail Pharmacy' will reach $28.55 billion. The estimate indicates a change of +3.5% from the prior-year quarter.
The average prediction of analysts places 'Revenues- International' at $5.83 billion. The estimate indicates a year-over-year change of +3.2%.
It is projected by analysts that the 'Revenues- U.S. Healthcare' will reach $2.06 billion. The estimate suggests a change of +25.8% year over year.
View all Key Company Metrics for Walgreens here>>>
Walgreens shares have witnessed a change of -5.3% in the past month, in contrast to the Zacks S&P 500 composite's +3.1% move. With a Zacks Rank #4 (Sell), WBA is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>